ConocoPhillips (COP) Stock Forecast
Data as of Sep 16, 2026Energy · Current price $140.51 (+2.84%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 27, 2026 | Devin McDermott | Morgan Stanley | $149.00 | +6.0% |
| Feb 6, 2026 | Sam Margolin | Wells Fargo | $133.00 | -5.3% |
| Jan 8, 2026 | Ryan Todd | Piper Sandler | $109.00 | -22.4% |
| Nov 24, 2025 | Ryan Todd | Piper Sandler | $115.00 | -18.2% |
| Nov 6, 2025 | Doug Leggate | Wolfe Research | $131.00 | -6.8% |
| Oct 14, 2025 | Devin McDermott | Morgan Stanley | $122.00 | -13.2% |
| Oct 13, 2025 | Lloyd Byrne | Jefferies | $120.00 | -14.6% |
| Oct 12, 2025 | Lloyd Byrne | Jefferies | $124.00 | -11.7% |
| Aug 7, 2025 | Leo Mariani | Roth Capital | $108.00 | -23.1% |
| Jul 15, 2025 | Devin McDermott | Morgan Stanley | $119.00 | -15.3% |
| Jul 11, 2025 | Paul Cheng | Scotiabank | $100.00 | -28.8% |
| Apr 15, 2025 | Devin McDermott | Morgan Stanley | $116.00 | -17.4% |
| Jan 30, 2025 | Neil Mehta | Goldman Sachs | $132.00 | -6.1% |
| Jan 14, 2025 | Roger Read | Wells Fargo | $132.00 | -6.1% |
| Nov 1, 2024 | Biju Perincheril | Susquehanna | $148.00 | +5.3% |
| Oct 11, 2024 | Ryan Todd | Piper Sandler | $135.00 | -3.9% |
| Oct 11, 2024 | Nitin Kumar | Mizuho Securities | $129.00 | -8.2% |
| Sep 4, 2024 | Biju Perincheril | Susquehanna | $147.00 | +4.6% |
| Aug 18, 2024 | Betty Jiang | Barclays | $156.00 | +11.0% |
| Jun 5, 2024 | Nitin Kumar | Mizuho Securities | $132.00 | -6.1% |
Top Analysts Covering COP
COP vs Sector & Market
| Metric | COP | Energy Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.17 | 2.51 | 2.42 |
| Analyst Count | 24 | 9 | 18 |
| Target Upside | +10.2% | +101.2% | +19.5% |
| P/E Ratio | 23.90 | 35.33 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $56.76B | $64.20B | $75.10B | 5 |
| 2027-12-31 | $59.45B | $62.13B | $66.31B | 5 |
| 2028-12-31 | $62.87B | $64.57B | $66.26B | 3 |
| 2029-03-31 | $15.92B | $19.08B | $24.53B | 2 |
| 2029-06-30 | $16.37B | $19.62B | $25.22B | 2 |
| 2029-09-30 | $16.83B | $20.17B | $25.93B | 2 |
| 2029-12-31 | $17.30B | $20.73B | $26.66B | 2 |
| 2030-03-31 | $17.79B | $21.32B | $27.41B | 2 |
| 2030-06-30 | $18.29B | $21.92B | $28.18B | 2 |
| 2030-09-30 | $18.80B | $22.53B | $28.97B | 2 |
| 2030-12-31 | $19.33B | $23.16B | $29.79B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.81 | $8.25 | $12.22 | 12 |
| 2027-12-31 | $4.95 | $8.20 | $10.96 | 12 |
| 2028-12-31 | $6.88 | $9.01 | $12.25 | 6 |
| 2029-03-31 | $1.48 | $1.89 | $2.59 | 5 |
| 2029-06-30 | $1.47 | $1.87 | $2.56 | 7 |
| 2029-09-30 | $1.47 | $1.87 | $2.56 | 4 |
| 2029-12-31 | $1.51 | $1.93 | $2.64 | 4 |
| 2030-03-31 | $1.51 | $1.92 | $2.64 | 6 |
| 2030-06-30 | $1.50 | $1.91 | $2.61 | 8 |
| 2030-09-30 | $1.55 | $1.97 | $2.70 | 4 |
| 2030-12-31 | $1.60 | $2.03 | $2.79 | 4 |
Frequently Asked Questions
What is the analyst consensus for COP?
The consensus among 24 analysts covering ConocoPhillips (COP) is Buy with an average price target of $150.82.
What is the highest price target for COP?
The highest price target for COP is $166.00, set by Josh Silverstein at UBS on 2024-05-30.
What is the lowest price target for COP?
The lowest price target for COP is $70.00, set by Alastair Syme at Citigroup on 2021-06-30.
How many analysts cover COP?
24 analysts have issued ratings for ConocoPhillips in the past 12 months.
Is COP a buy or sell right now?
Based on 24 analyst ratings, COP has a consensus rating of Buy (2.17/5) with a +10.2% upside to the consensus target of $150.82.
What are the earnings estimates for COP?
Analysts estimate COP will report EPS of $8.25 for the period ending 2026-12-31, with revenue estimated at $64.20B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.